MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Becton Dickinson and Co

Abierto

SectorSanidad

203.21 -0.14

Resumen

Variación precio

24h

Actual

Mínimo

201.79

Máximo

204.89

Métricas clave

By Trading Economics

Ingresos

-118M

303M

Ventas

-272M

5.2B

P/B

Media del Sector

33.099

57.333

BPA

3.43

Rentabilidad por dividendo

2

Margen de beneficios

5.863

Empleados

70,000

EBITDA

-1.3B

453M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+31.64% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.00%

2.63%

Próximas Ganancias

1 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-15B

56B

Apertura anterior

203.35

Cierre anterior

203.21

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Becton Dickinson and Co Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 feb 2025, 22:09 UTC

Adquisiciones, fusiones, absorciones

Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business

7 nov 2024, 12:59 UTC

Ganancias

Becton Dickinson Profit Rises as Acquisition Buoys Sales - Update

7 nov 2024, 12:56 UTC

Ganancias

Becton Dickinson Fiscal 4Q Profit Rises as Acquisition Buoys Sales

1 ago 2024, 11:08 UTC

Ganancias

Becton 3Q Adjusted Earnings Top Views But International Sales Weigh on FY24 Outlook

3 jun 2024, 11:18 UTC

Adquisiciones, fusiones, absorciones

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion in Cash

5 feb 2025, 21:56 UTC

Ganancias

Correct: Becton Dickinson Sees 2025 Adj EPS $14.30-Adj EPS $14.60 >BDX

5 feb 2025, 21:54 UTC

Ganancias

Becton Dickinson Sees 2025 EPS $14.30-EPS $14.60 >BDX

5 feb 2025, 21:54 UTC

Ganancias

Becton Dickinson Sees 2025 GAAP Rev Growth 7.9% to 8.4% >BDX

5 feb 2025, 21:53 UTC

Ganancias

Becton Dickinson Sees 2025 Rev $21.7B-$21.9B >BDX

5 feb 2025, 21:30 UTC

Ganancias

Becton Dickinson 1Q Adj EPS $3.43 >BDX

5 feb 2025, 21:30 UTC

Ganancias

Becton Dickinson 1Q Rev $5.2B >BDX

5 feb 2025, 21:30 UTC

Ganancias

Becton Dickinson 1Q Net $303M >BDX

5 feb 2025, 21:30 UTC

Ganancias

Becton Dickinson 1Q EPS $1.04 >BDX

7 nov 2024, 11:36 UTC

Ganancias

Becton Dickinson Sees FY25 Rev $21.9B-$22.1B >BDX

7 nov 2024, 11:35 UTC

Ganancias

Becton Dickinson Sees FY25 Adj EPS $14.25-Adj EPS $14.60 >BDX

7 nov 2024, 11:30 UTC

Ganancias

Becton Dickinson 4Q EPS $1.45 >BDX

7 nov 2024, 11:30 UTC

Ganancias

Becton Dickinson 4Q Adj EPS $3.81 >BDX

7 nov 2024, 11:30 UTC

Ganancias

Becton Dickinson 4Q Rev $5.4B >BDX

7 nov 2024, 11:30 UTC

Ganancias

Becton Dickinson 4Q Cont Ops EPS $1.45 >BDX

1 ago 2024, 10:37 UTC

Ganancias

Becton Dickinson Now Sees FY24 Revenue About $20.1B; Had Seen $20.1B-$20.3B >BDX

1 ago 2024, 10:35 UTC

Ganancias

Becton Dickinson Sees FY24 Revenue Up About 3.7%, Organic Revenue Up 5%-5.25% >BDX

1 ago 2024, 10:35 UTC

Ganancias

Becton Dickinson Sees FY24 Adj EPS $13.05-Adj EPS $13.15 >BDX

1 ago 2024, 10:30 UTC

Ganancias

Becton Dickinson 3Q EPS $1.68 >BDX

1 ago 2024, 10:30 UTC

Ganancias

Becton Dickinson 3Q Net $487M >BDX

1 ago 2024, 10:30 UTC

Ganancias

Becton Dickinson 3Q Adj EPS $3.50 >BDX

1 ago 2024, 10:30 UTC

Ganancias

Becton Dickinson 3Q Rev $5B >BDX

4 jun 2024, 17:26 UTC

Adquisiciones, fusiones, absorciones

Edwards Lifesciences Deal A Clear Win For Becton Dickinson, Analysts Say -- Analysis

3 jun 2024, 15:30 UTC

Acciones populares

Stocks to Watch Monday: GameStop, AMC, Paramount, Nvidia -- WSJ

3 jun 2024, 13:26 UTC

Adquisiciones, fusiones, absorciones

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal -- IBD

3 jun 2024, 12:25 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash -- Update

Comparación entre iguales

Cambio de precio

Becton Dickinson and Co previsión

Precio Objetivo

By TipRanks

31.64% repunte

Estimación a 12 Meses

Media 269.13 USD  31.64%

Máximo 280 USD

Mínimo 260 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Becton Dickinson and Co Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

8

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

199.12 / 207.26Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.